| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Advanced mutation and copy number variation evaluation
For cases of suspected hereditary hearing loss, which encompass a heterogenous group of syndromic and nonsyndromic conditions, comprehensive genetic testing can determine molecular etiology. Confirmation of the genetic cause clarifies whether the loss is nonsyndromic or syndromic, in which case other organ systems might be involved. This testing also can establish a long-term prognosis as well as ascertain inheritance pattern and recurrence risk within a family.
A team of hearing loss experts, genetic counselors, and laboratorians developed our comprehensive genetic hearing loss panel with disease management in mind. By only including genes with clear associations to hearing loss, our tests provide accurate answers to optimize patient outcomes.
Expertly curated panels
Our panels were carefully curated and vetted by a multidisciplinary team of board-certified Mayo Clinic epileptologists and geneticists to only include clinically significant genes known to be causal for epilepsy when mutated. This ensures any pathogenic variants identified are actionable and reduce the noise of false positive or ambiguous results.
Complete and high-density coverage
Our laboratory testing offers greater breadth and depth of coverage for every base at each exon in every gene. This ensures the highest possible sensitivity for the detection of sequence-level mutations, which reduces false negative results.
Comprehensive CNV analysis
CNVs account for 10% to 20% of all pathogenic mutations associated with epilepsy.1,2 Using an internally developed algorithm for CNV detection, and leveraging our high depth of coverage, we demonstrated 100% sensitivity and greater than 99.9% specificity for the detection of CNVs across a large sample set during test validation.
The primary goal of our clinical reports is communicating test results and their implications to patients in a clear, concise manner that is easily digestible by ordering clinicians.
These tests are useful for establishing a diagnosis of an epilepsy or seizure disorder associated with known causal genes, and identifying mutations within genes known to be associated with inherited epilepsy or seizure disorders, allowing for predictive testing of at-risk family members.
Epilepsy Expanded Panel, 192 genes
Our most comprehensive panel analyzes genes associated with all causes of epilepsy
Early Epileptic Encephalopathy Panel, 90 genes
Epileptic encephalopathies are neurodevelopmental disorders caused by recurrent clinical seizures usually seen during the early infantile period
Encephalopathy with Seizures Panel, 129 genes
This panel is targeted towards those cases of encephalopathy with an onset outside of the neonatal and infantile periods
Epilepsy with Migraine Panel, 7 genes
Targeted toward epilepsy patients also experienced migraine
Febrile Seizure Panel, 9 genes
Aimed at epilepsy patients with febrile seizures, which is the most common convulsive event in childhood, that usually occur between 3 months and 5 years of age and is the presenting symptom of many clinical epilepsy syndromes
Focal Epilepsy Panel, 16 genes
For patients with focal epilepsy, a neurological disorder characterized by recurrent seizures with abnormal electrographic activity in localized brain areas
Infantile Spasms Panel, 17 genes
A panel for Infantile Spasm patients. Infantile spasms are the most frequent type of epilepsy in the first year of life.
Neuronal Migration Disorders Panel, 29 genes
Neuronal migration disorders include lissencephaly, heterotopia, polymicrogyria, schizencephaly, and focal cortical dysgenesis.
Progressive Myoclonic Epilepsy Panel, 27 genes
Progressive myoclonic epilepsies are a genetically heterogeneous group of disorders that are characterized by worsening action myoclonus, epileptic seizures, and a progressive neurologic decline.
Tuberous Sclerosis Panel, 2 genes
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous multisystem disorder associated with mutations in the TSC1 and TSC2 genes.
Custom Gene Ordering
Our custom gene ordering allows the creation of a custom gene list to tailor testing to a patient’s exact need. After selection of a specific disease state, the custom gene panel can be modified to add or remove genes. Through this option, single gene testing can be performed.
Learn more about how to order these tests at your institution.
